BackNuvation Bio Overview

Nuvation Bio Inventory

Nuvation Bio's inventory is $15M.

Get informed when a big investor buys or sells

+ Follow
Inventory
$15.34M
↑ 168.60% YoYΔ $9.63M vs prior year quarter

Peer trimmed avg / median

Loading

Nuvation Bio Inventory History

Loading

Nuvation Bio vs. peers: Inventory Comparison

Loading

Nuvation Bio Inventory Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Nuvation Bio (NUVB) FAQ

As of the most recent data (September 2026), NUVB shows a inventory of $15M. That compares with $5.7M in the prior-year period — up 168.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NUVB's inventory is now $15M (was $5.7M) — a 168.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Nuvation Bio is outperforming or lagging.

Tracking NUVB's inventory over time shows whether Nuvation Bio is scaling, shrinking, or reshaping that part of the business. The current reading is $15M That compares with $5.7M in the prior-year period — up 168.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this inventory page, Stockcircle has Nuvation Bio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect inventory (currently $15M) with ownership activity and broader fundamentals.

Nuvation Bio's inventory is $15M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.